In testimony Wednesday, former Trump attorney Michael Cohen testified he had spoken to Novartis six times. Rep. Mark Meadows issued a referral for criminal investigation over contacts with Novartis and Kazakhstan's BTA Bank.
The Senate Finance Committee grilled executives from seven of the biggest drugmakers about the dramatic rise in drug costs.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The industrial conglomerate said the move was designed to reduce its leverage and improve its balance sheet. The company carried almost $115 billion in debt during the first nine months of 2018.
The proposed rule, which will be officially published on Wednesday, is part of the Trump administration's blueprint for reducing out-of-pocket drug prices. However, others have said it could raise premiums and have doubted how much power the administration truly has.
The study, published last week, found that high price points didn't deter consumers when coupled with the potential for financial assistance.
Generics industry trade group the Association for Accessible Medicines anticipates that the CREATES Act could see action in Congress next year amid bipartisan support for tackling drug costs.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
In a speech at a University of Southern California-Brookings Institution event, Seema Verma pointed to 2016 figures showing more than $1 billion in missed savings.
A legal expert compared mandatory prices in ads to food labeling, but another expert said mandating them risks scaring patients out of taking life-saving medicines.
The industry's main lobbying group, PhRMA, updated its direct-to-consumer ad guidelines to include pricing information, but HHS secretary says voluntary action is insufficient.
Amid the drug pricing debate, the findings show that trials can be run at relatively low cost and still generate high-quality data, the study's lead author said.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Check out Friday's MedHeads and catch up on the top stories of the week.
A subsidiary of Florida’s largest insurer led a series B round for a digital health group that uses a selection of patient engagement tools to improve outcomes. Audax Health Solutions raised $20 million in a round led by Navigy Holdings, a subsidiary of Blue Cross and Blue Shield of Florida. Navigy identifies health system inefficiencies […]
Some people bristle at descriptions of patients as “consumers,” as if patients want to be in a hospital. Physicians need to be trained to be more empathetic and do a better job of reading and responding to their patients’ emotional cues. These were just a couple of the insights exchanged among a panel of patient […]
President Barack Obama’s announcement detailing the $100 million project to map the human brain has caused ripples of excitement through the biotech, big data and epatient communities. But that excitement has been tempered by a certain amount of trepidation over how this project will impact life science researchers counting on government funding for their own […]
The mHealth Summit next week should spark some interesting discussions on partnerships between health IT firms and providers, the quantified self, remote monitoring and clinical trials, among other topics. To keep up with the Twitter chatter insight exchange, whether you’re on the ground at Gaylord Convention Center by Washington, D.C., or you’re doing some remote […]